Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

News & Events

: Press Releases

Home
News & Events
Press Releases

Press Releases

Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York

April 4, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD

April 3, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL

March 21, 2018 • 4:05 PM EDT

Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

March 13, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update

March 12, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference

March 6, 2018 • 7:00 AM EST

Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors

February 15, 2018 • 7:00 AM EST

Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City

February 7, 2018 • 4:30 PM EST

Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale

January 24, 2018 • 4:30 PM EST

Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

January 23, 2018 • 7:00 AM EST

1
2
3
4
5
6
7
8
9
10
...23
Next »

News & Events : Press Releases